BioMarin

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. 

CEO
Alexander Hardy
CEOAlexander Hardy
Employees
3,221
Employees3,221
Headquarters
San Rafael, California
HeadquartersSan Rafael, California
Founded
1997
Founded1997
Employees
3,221
Employees3,221

BMRN Key Statistics

Market cap
10.40B
Market cap10.40B
Price-Earnings ratio
29.96
Price-Earnings ratio29.96
Dividend yield
—
Dividend yield—
Average volume
1.43M
Average volume1.43M
High today
$54.29
High today$54.29
Low today
$53.56
Low today$53.56
Open price
$53.95
Open price$53.95
Volume
1.34M
Volume1.34M
52 Week high
$66.28
52 Week high$66.28
52 Week low
$50.76
52 Week low$50.76

Stock Snapshot

With a market cap of 10.4B, BioMarin(BMRN) trades at $54.06. The stock has a price-to-earnings ratio of 29.96.

During the trading session on 2026-05-03, BioMarin(BMRN) shares reached a daily high of $54.29 and a low of $53.56. At a current price of $54.06, the stock is +0.9% higher than the low and still -0.4% under the high.

Trading activity shows a volume of 1.34M, compared to an average daily volume of 1.43M.

The stock's 52-week range extends from a low of $50.76 to a high of $66.28.

The stock's 52-week range extends from a low of $50.76 to a high of $66.28.

BMRN News

Simply Wall St 2d
Assessing BioMarin Valuation As Shares Show Recent Weakness And DCF Signals Deep Discount

Advertisement Recent performance snapshot BioMarin Pharmaceutical (BMRN) has drawn fresh attention after recent trading, with the share price at US$54.06 and...

Assessing BioMarin Valuation As Shares Show Recent Weakness And DCF Signals Deep Discount
Simply Wall St 3d
BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset

BioMarin Pharmaceutical (NasdaqGS:BMRN) has completed its acquisition of Amicus Therapeutics. The deal adds two approved lysosomal storage disease treatments t...

BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset
Simply Wall St 4d
BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust

BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, previously listed as NasdaqGM:FOLD. Following the transaction, Amicus has been de...

BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust

Analyst ratings

81%

of 27 ratings
Buy
81.5%
Hold
18.5%
Sell
0%

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.
Salesforce
Pfizer
Alibaba
PayPal
Disney
Moderna

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.